Comvita

Comvita, a Pharmaceutical Preparation Manufacturing company based in New Zealand, reported approximately 26,079,000 kg CO2e in total gross carbon emissions for 2024. This total includes Scope 1 emissions of about 1,052,000 kg CO2e, Scope 2 emissions (location-based) of approximately 308,000 kg CO2e, and Scope 3 emissions of about 24,719,000 kg CO2e. The largest contributor to Scope 3 emissions was purchased goods and services, accounting for around 19,125,000 kg CO2e.

In 2023, Comvita's total gross carbon emissions were approximately 34,944,000 kg CO2e. This comprised Scope 1 emissions of about 1,113,000 kg CO2e, Scope 2 emissions (location-based) of approximately 349,000 kg CO2e, and Scope 3 emissions of around 33,482,000 kg CO2e, with purchased goods and services being the dominant factor.

For 2022, Comvita recorded total gross carbon emissions of approximately 32,004,000 kg CO2e, which included Scope 1 emissions of about 1,022,000 kg CO2e, Scope 2 emissions (location-based) of approximately 429,000 kg CO2e, and Scope 3 emissions of around 30,553,000 kg CO2e. Purchased goods and services were also the largest component of Scope 3 emissions in this year.

Comvita has previously stated an aspiration to achieve carbon neutrality for Scope 1 and Scope 2 emissions by fiscal year 2025. The company also set a science-aligned target in 2021 to reduce its New Zealand Scope 1 and Scope 2 emissions by 50% by 2030. Comvita Limited has committed to Net-Zero and was a BA1.5 member as of March 2023, as per the Science Based Targets initiative (SBTi).